

**Supplementary Information files**  
**CEA Dynamics for Predicting Response after Anti-EGFR Monoclonal**  
**Antibody Treatment in Metastatic Colorectal Cancer**

Sora Kang<sup>1,2</sup>, Sun Young Kim<sup>1</sup>, Yong Sang Hong<sup>1</sup>, Tae Won Kim<sup>1</sup>, Ki Eun Choi<sup>1</sup>, Min Jung Kim<sup>1</sup>, Jeong Eun Kim<sup>1</sup>

<sup>1</sup>Department of Medical Oncology, Asan Medical Center, University of Ulsan College of Medicine, Seoul, South Korea

<sup>2</sup>Division of hemato-oncology, Department of Internal Medicine, Chungnam National University Hospital, Daejeon, South Korea.

**Correspondence:**

Jeong Eun Kim, M.D., Ph.D.


Department of Medical Oncology

Asan Medical Center, University of Ulsan College of Medicine


88, Olympic-ro 43-gil, Songpa-gu, Seoul 05505, South Korea

Tel: +82-2-3010-3945; Fax: +82-2-3010-6961


E-mail: jeongeunkim@amc.seoul.kr



**Supplementary Figure S1.** CONSORT diagram of the included patients.



**Supplementary figure S2.** (a) Progression-free survival (PFS) and (b) overall survival (OS) according to the serum carcinoembryonic antigen (CEA) cut-off value for patients treated with chemotherapy plus anti-vascular endothelial growth factor (VEGF) monoclonal antibody (mAb).



**Supplementary figure S3.** (a) Progression-free survival (PFS) and (b) overall survival (OS) according to the carcinoembryonic antigen (CEA) cut-off value in patients treated with chemotherapy alone.

Supplementary Table 1. First line chemotherapy regimen in the study patients according to the treatment group

|                                        |                    |
|----------------------------------------|--------------------|
| <b>Chemotherapy alone group</b>        | <b>n = 891 (%)</b> |
| FOLFIRI                                | 354 (40%)          |
| FOLFOX                                 | 305 (34%)          |
| SOX                                    | 25 (2.8%)          |
| XELOX                                  | 207 (23%)          |
| <b>Chemotherapy plus anti-VEGF mAb</b> | <b>n = 266 (%)</b> |
| Bevacizumab + FOLFIRI                  | 181 (68%)          |
| Bevacizumab + FOLFOX                   | 85 (32%)           |
| <b>Chemotherapy plus anti-EGFR mAb</b> | <b>n = 104 (%)</b> |
| Cetuximab + FOLFIRI                    | 86 (83%)           |
| Cetuximab + FOLFOX                     | 18 (17%)           |

Abbreviations: mAb, monoclonal antibodies; FOLFIRI, Folinic acid, fluorouracil, and irinotecan; FOLFOX, Folinic acid, fluorouracil, and oxaliplatin; SOX, S-1 and oxaliplatin; XELOX, capecitabine, and oxaliplatin.